Faculty ProfilesAmy Lin, MD
550 16th Street
San Francisco, CA 94158
Amy M Lin is a genitourinary medical oncologist who joined the UCSF faculty in 2005. Dr. Lin works with a multidisciplinary team of medical oncologists, radiation oncologists, and urologic surgical oncologists at UCSF and the San Francisco Veterans Administration Medical Center where she sees all types of genitourinary malignancies including prostate, kidney, bladder and testicular cancer. Dr. Lin is also a member of the core UCSF Cancer Immunotherapy Clinic team and cares for patients with all cancer types on novel immunotherapy studies. She is currently an Associate Professor of Medicine and Urology.
Dr. Lin's focus is on improving clinical care workflows to optimize health care delivery. She is interested in how health care technology can enhance certain aspects of patient care and believes that increasing the quality of health care data collection, integration of multi-source patient health care data, and data interoperability are key to these efforts. Dr. Lin has been an active subject matter expert on electronic health record (EHR) clinical workflows within the Cancer Center. She is also a member of the American Society of Clinical Oncology (ASCO) CancerLinQ Research and Publications Committee which is a large scale national effort to collect and analyze real world (non-clinical trial) oncology patient data and outcomes.
Education and Training
|Location||Degree or Training||Specialty||Date|
|University of California, San Francisco||Fellowship||Oncology: Genitourinary Medical Oncology||2006|
|New York Presbyterian Hospital Cornell||Residency||Internal Medicine||2002|
|University of Chicago Pritzker||M.D.||School of Medicine||1999|
|Oregon Health Sciences University||Graduate certificate||Biomedical and Health Informatics|
clinical workflow, data standards, digital health, health care data interoperability, health care informatics, health care technologyAwards and Honors
 Top Doctors, Marin Magazine, 2015-2017
Pinnacle "Voice of the Patient" Team Award, University of California San Francisco, 2015
Young Investigator Award, Cancer and Leukemia Group B (CALGB), 2007
Prostate Cancer Symposium Merit Award, American Society of Clinical Oncology, 2005
Young Investigator Award, American Society of Clinical Oncology, 2005
Clinical Cancer Research Workshop, AACR/ASCO, 2004
Calvin Fentress Research Fellowship Award, University of Chicago, 1998
Elizabeth Agassiz Award, Harvard University, 1992
John Harvard Scholarship for Academic Excellence, Harvard University, 1991
Harvard College Scholarship, Harvard University, 1990
Recent Articles (23)
Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ. A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018 Feb 27.
Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):733-741.e1.
Wei XX, Hsieh AC, Kim W, Friedlander T, Lin AM, Louttit M, Ryan CJ. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 May; 22(5):503-e43.
Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Apr; 35(4):149.e7-149.e13.
Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958.
Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16.
Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8.
Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9.
Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90.
Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14.
Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15.
Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8.
Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9.